Metastasis Risk Reduction Related with Beta-Blocker Treatment in Mexican Women with Breast Cancer

  • Published : 2016.06.01


Background: Breast Cancer (BCa) is the most common malignant tumour in Mexican women. In BCa, several studies have linked ${\beta}2-adrenergic$ receptor activation with increased tumour growth and progression as related with Epinephrine-NorEpinephrine (E-NE) stimulation. The aim of this study was to describe Beta-Blocker (BB) treatment related with reduction of the risk of metastasis in Mexican patients with BCa. Materials and Methods: We collected data of 120 patients seen at the High-Specialty Naval General Hospital in Mexico City (HOSGENAES), all of these with a histopathological diagnosis of BCa. Four groups of patients were divided as follows: without Systemic Arterial Hypertension (SAH); with SAH treatment with non-selective BB; with SAH treatment with selective BB, and with SAH treatment with other antihypertensive drugs. Chi-square, Mantel-Haenszel, Student t, and ANOVA tests were performed for data analysis. Results: On average, patients were $54.8{\pm}11.8$ years of age. Risk factors such as smoking and consuming alcohol exhibited a frequency of 33 and 36.5% respectively. Clinical stages III- IV were found in 50% of patients, while, 30% of patients had arterial hypertension (n=29 and N=96, respectively) and 17.5% used BB. One hundred percent of patients with arterial hypertension treated with BB for ${\beta}1$ - and ${\beta}2$ -adrenergic-receptors did not present metastasis globally, but patients treated with ${\beta}1$ BB presented 30% of metastasis while patients treated with no BB or without SAH had around 70% of metastasis. Conclusions: In Mexican patients with BCa and SAH treated with non-selective (${\beta}1$- and ${\beta}2-adrenergic$ receptors) BB, a decrease in the risk for metastasis was observed at the time of diagnosis.


  1. Doval DC, Sharma A, Sinha R, et al (2015). Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev, 16, 4959-64.
  2. Drell TL, Joseph J, Lang K, et al (2003). Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat, 80, 63-70.
  3. Floriano-Sanchez E, Rodriguez NC, Bandala C, et al (2014). CYP3A4 expression in breast cancer and its association with risk factors in Mexican women. Asian Pac J Cancer Prev, 15, 3805-9.
  4. Gates MA, Xu M, Chen WY, et al (2012). Wolpin BM. ABO blood group and breast cancer incidence and survival. Int J Cancer, 130, 2129-37.
  5. Ji Y, Sheng L, Du X, et al (2014). Clinicopathological variables predicting HER-2 gene status in immunohistochemistryequivocal (2+) invasive breast cancer. J Thorac Dis, 6, 896-904.
  6. Justo N, Wilking N, Jonsson B, et al (2013). A review of breast cancer care and outcomes in Latin America. Oncol, 18, 248-56.
  7. Cabrero A, Picon G, Gisela K, et al (2010). Cancer de mama metastasico: estudio clinico-patologico de 300 casos. Patologia, 48, 18-22.
  8. Cardenas-Rodriguez N, Lara-Padilla E, Bandala C, et al (2012). CYP2W1, CYP4F11 and CYP8A1 polymorphisms and interaction of CYP2W1 genotypes with risk factors in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 837-46.
  9. Cole SW, Sood AK (2012). Molecular pathways: beta-adrenergic signaling in cancer. Clinical Cancer Res, 18, 1201-6.
  10. Dey S (2014). Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal. World J Clin Oncol, 5, 509-19.
  11. Dimitrakopoulos FI, Kottorou A, Antonacopoulou AG, et al (2015). Early-stage breast cancer in the elderly: confronting an old clinical problem. J Breast Cancer, 18, 207-17.
  12. Direccion General de Información en Salud (DGIS). Base de datos de defunciones 1979-2009. Sistema Nacional de Informacion en Salud (SINAIS).
  13. Zhang D, Ma Q, Wang Z, et al (2011). ${\beta}2$-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/$NF{\kappa}B$ pathway. Molecular Cancer, 10, 146
  14. Alanazi I, Khan Z (2016). Understanding EGFR signaling in breast cancer and breast cancer stem cells: overexpression and therapeutic implications. Asian Pac J Cancer Prev, 17, 445-53.
  15. Anaya-Ruiz M, Vallejo-Ruiz V, Flores-Mendoza L, et al (2014). Female breast cancer incidence and mortality in Mexico, 2000-2010. Asian Pac J Cancer Prev, 15, 1477-9.
  16. American Cancer Society. Breast Cancer Facts & Figures 2011 Y 2012. Atlanta: American Cancer Society, Inc; 2013.
  17. Bandala C, Floriano-Sanchez E, Cardenas-Rodriguez N, et al (2012). RNA expression of cytochrome P450 in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 2647-53.
  18. Barron TI, Sharp L, Visvanathan K (2012). Beta-adrenergic blocking drugs in breast cancer: a perspective review. Therapeutic Advances Med Oncol, 4, 113-25.
  19. Keyhani E, Muhammadnejad A, Behjati F, et al (2013). Pazhoomand. Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents. Asian Pac J Cancer Prev, 14, 7651-6.
  20. Lutgendorf S, Sood A (2011). Biobehavioral Factors and Cancer Progression: Physiological Pathways and Mechanisms. Psychosom Med, 73, 724-30.
  21. Lyon: International Agency for Research on Cancer; 2013.
  22. Maschio LB, Madallozo BB, Capellasso BA, et al (2014). Immunohistochemical investigation of the angiogenic proteins VEGF, HIF-$1{\alpha}$ and CD34 in invasive ductal carcinoma of the breast. Acta Histochem, 116, 148-57.
  23. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al (2011). Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol, 29, 2645-52.
  24. Tang J, Li Z, Lu L, et al (2013). Seminars in Cancer Biology ${\beta}$-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol, 23, 533-42.
  25. Tirona MT, Sehgal R, Ballester O (2010). Prevention of breast cancer (part I): Epidemiology, risk factors, and risk assessment tools. Cancer Invest, 28, 743-50.
  26. Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al (2013). Breast cancer in young women in Latin America: an unmet, growing burden. Oncol, 18, 1298-306.
  27. Wang T, Li Y, Lu HL, et al (2016). ${\beta}$-adrenergic receptors: New target in breast cancer. Asian Pac J Cancer Prev, 16, 8031-39.
  28. Yang E, Bane CM, MacCallum RC, et al (2002). Stress-related modulation of matrix metalloproteinase expression. J Neuroimmunology, 133, 144-50.
  29. Pervaiz F, Rehmani S, Majid S, et al (2015). Evaluation of Hormone Receptor Status (ER/PR/HER2-neu) in Breast Cancer in Pakistan. J Pak Med Assoc, 65, 747-52.
  30. Petric M, Martinez S, Acevedo F, et al (2014). Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy. Asian Pac J Cancer Prev, 15, 10277-80.
  31. Quoc Lu'o'ng KV, Nguyen LT (2012). The roles of betaadrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. Cancer Management Res, 4, 431-45.
  32. Rummel S, Shriver CD, Ellsworth RE (2012). Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study. BMC Med Genet, 13, 41.
  33. Sood AK, Bhatty R, Kamat AA, et al (2006). Stress hormone mediated invasion of ovarian cancer cells. Clin Cancer Res, 12, 369-75.